The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
This federal Project Grant award of $781,718 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of a novel T cell-based vaccine to prevent Dengue virus (DENV) and Zika virus (ZIKV) infection. The research team at Loyola University of Chicago's Health Sciences Campus will design a vaccine that targets the ZIKV non-structural protein 3 (NS3) without the precursor membrane (PrM) and envelope (E)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $137,229 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Chulalongkorn University in Thailand. The grant, which runs from August 2024 to July 2029, focuses on two key objectives: Characterizing the host response and identifying novel biomarkers to accurately predict the severity of acute leptospirosis, a potentially life-threatening zoonotic disease. This will involve a...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA 93.855 Allergy and Infectious Diseases Research, provides $230,000.00 to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The key focus is on evaluating recently discovered neuraminidase (NA) broadly neutralizing antibodies (bnAbs) for their potential in a germline targeting vaccine design approach. This research aims to prime rare precursor B cells...
This Project Grant award, totaling $859,597, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award aims to develop a vaccine that can elicit broadly neutralizing antibodies (bNAbs) against the HIV-1 fusion peptide epitope, a major vulnerable site on the viral envelope protein. The key product being developed is a recombinant fusion immunogen combining the HIV-1 fusion peptide with...
This Project Grant award of $755,225.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a unique vaccine to prevent future pandemics caused by emerging coronavirus (CoV) strains. The goal is to design a mucosal CoV vaccine that targets conserved CoV antigens (S2, M, N) to induce protective T-cell responses, particularly tissue-resident memory T cells in the upper...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $813,160 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to George Washington University to develop mRNA-LNP combination vaccines targeting multiple stages and species of the human malaria parasite. The goal is to create vaccines that provide effective immune protection against malaria infection and reduce disease transmission. The project will evaluate protective efficacy of...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $13,946,446 Cooperative Agreement titled "PROVIDENT: PREPOSITIONING OPTIMIZED STRATEGIES FOR VACCINES AND IMMUNOTHERAPEUTICS AGAINST DIVERSE EMERGING INFECTIOUS THREATS" to the Albert Einstein College of Medicine. The overarching goal of this 5-year project is to deliver "plug-and-play" vaccine and therapeutic antibody...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $390,942 to the Georgia TECH Research Corp to develop a universal influenza vaccine using self-assembled peptide nanoparticles (SAPNs). The goal is to present conserved influenza antigens, including the hemagglutinin stalk (HRHA) and matrix protein 2 ectodomain (4M2E), in a highly repetitive array on the SAPN...
This Project Grant award of $3,156,840, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding research to develop a universal vaccine against leptospirosis. The primary awardee, the University of Connecticut, is leading efforts to evaluate a multi-recombinant protein vaccine candidate that has demonstrated cross-protective immunity against multiple pathogenic Leptospira species in animal models. The project involves sub-awards to Serimmune Inc. to identify conserved B-cell epitopes, and to the University of California, Irvine and Yale University to characterize the T-cell and humoral immune responses elicited by the vaccine candidate. The goal is to establish a potential generalizable vaccine that can prevent transmission and disease in both humans and domestic animals. This research aims to address a critical knowledge gap in developing an effective universal leptospirosis vaccine that can provide significant public health and economic benefits.